The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Isocitrate dehydrogenase mutations in gliomas
Open accessAbstract
Over the last decade, extraordinary progress has been made in elucidating the underlying genetic causes of gliomas. In 2008, our understanding of glioma genetics was revolutionized when mutations in isocitrate dehydrogenase 1 and 2 (IDH1/2) were identified in the vast majority of progressive gliomas and secondary glioblastomas (GBMs). IDH enzymes normally catalyze the decarboxylation of isocitrate to generate α-ketoglutarate (αKG), but recurrent mutations at Arg(132) of IDH1 and Arg(172) of IDH2 confer a neomorphic enzyme activity that catalyzes reduction of αKG into the putative oncometabolite D-2-hydroxyglutate (D2HG). D2HG inhibits αKG-dependent dioxygenases and is thought to create a cellular state permissive to malignant transformation by altering cellular epigenetics and blocking normal differentiation processes. Herein, we discuss the relevant literature on mechanistic studies of IDH1/2 mutations in gliomas, and we review the potential impact of IDH1/2 mutations on molecular classification and glioma therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Self-citationIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S.-H., Ito, S., Yang, C., Wang, P., Xiao, M.-T., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.12.014 · Cited by 2,875 · cited 4×
“Expression of IDH1 or treatment with cellpermeable D2HG has also been shown to increase HIF1a expression.(47) Similarly, inducible expression of IDH1 in the brains of embryonic mice causes increased HIF1a protein expression and increased steady-state levels of HIF1a-inducible genes such as VEGF and GLUT-1.”
BackgroundResultInfluentialFigueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A., Li, Y., Bhagwat, N., Vasanthakumar, A., Fernandez, H. F., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.015 · Cited by 2,766
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents
Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., Baylin, S. B., & Herman, J. G. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011093431901 · Cited by 2,224
Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.020 · Cited by 2,020
IDH mutation impairs histone demethylation and results in a block to cell differentiation
Lu, C., Ward, P. S., Kapoor, G. S., Rohle, D., Turcan, S., Abdel-Wahab, O., Edwards, C. R., Khanin, R., Figueroa, M. E., Melnick, A., et al. (2012) · Nature · doi:10.1038/nature10860 · Cited by 1,985
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., et al. (2012) · Nature · doi:10.1038/nature10866 · Cited by 1,974 · cited 1×
“For example, Turcan et al reported that WHO grade II/III gliomas exhibit a distinct G-CIMP phenotype that can be recapitulated by expressing IDH1 in human astrocytes.(51) A direct, mechanistic link between IDH mutations and DNA hypermethylation is provided by the observation that D2HG inhibits the activity of TET 5-me…”
BackgroundReductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791 · cited 2×
“IDH1 promotes lipogenesis during hypoxia by catalyzing the reductive carboxylation of aKG to generate acetyl-CoA for lipid synthesis.(5,6) Overexpression of IDH1 in liver and adipose tissue causes obesity, fatty liver, and hyperlipidemia in transgenic mice.”
BackgroundTET enzymes, TDG and the dynamics of DNA demethylation
Kohli, R. M., & Zhang, Y. (2013) · Nature · doi:10.1038/nature12750 · Cited by 1,623 · cited 1×
“3A and B).(52) Xu et al reported that expression of IDH1 or IDH2 decreases the abundance of 5-hmC in HEK293 cells by inhibiting the activity of TET1 and TET2 enzymes.”
BackgroundCairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,610
Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
Self-citationvan den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J.-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,226
Hartmann, C., Meyer, J., Balss, J., Capper, D., Mueller, W., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163
Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 2×
“Early reports suggested that IDH1/2 mutations caused a loss of normal oxidative catalytic function and dominant negative inhibition of the wild-type allele, which was supported by loss of NAPDHproducing activity and decreased affinity for isocitrate in mutant enzymes.(22,44) However, in 2009, Dang et al reported the g…”
BackgroundAnalysis of the IDH1 codon 132 mutation in brain tumors
Balss, J., Meyer, J., Mueller, W., Korshunov, A., Hartmann, C., & von Deimling, A. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0455-2 · Cited by 1,036
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases
Chowdhury, R., Yeoh, K. K., Tian, Y., Hillringhaus, L., Bagg, E. A., Rose, N. R., Leung, I. K. H., Li, X. S., Woon, E. C. Y., Yang, M., et al. (2011) · The EMBO Reports · doi:10.1038/embor.2011.43 · Cited by 1,035 · cited 4×
“Xu et al reported that D2HG competitively inhibits the histone demethylase JHDM1A, and administration of cell-permeable D2HG is sufficient to increase histone H3 and H3 methylation in U87MG GBM cells(47) and H3 trimethylation in HeLa cells.(48) Similarly, IDH1 or IDH2 expression increases trimethylation of histone H3…”
BackgroundInfluentialIDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027
Amary, M. F., Bacsi, K., Maggiani, F., Damato, S., Halai, D., Berisha, F., Pollock, R., O'Donnell, P., Grigoriadis, A., Diss, T., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2913 · Cited by 1,023
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas
Sanson, M., Marie, Y., Paris, S., Idbaih, A., Laffaire, J., Ducray, F., El Hallani, S., Boisselier, B., Mokhtari, K., Hoang-Xuan, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9832 · Cited by 1,008
Wise, D. R., Ward, P. S., Shay, J. E. S., Cross, J. R., Gruber, J. J., Sachdeva, U. M., Platt, J. M., DeMatteo, R. G., Simon, M. C., & Thompson, C. B. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117773108 · Cited by 975
Mutational landscape and clonal architecture in grade II and III gliomas
Suzuki, H., Aoki, K., Chiba, K., Sato, Y., Shiozawa, Y., Shiraishi, Y., Shimamura, T., Niida, A., Motomura, K., Ohka, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3273 · Cited by 831
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804
Paschka, P., Schlenk, R. F., Gaidzik, V. I., Habdank, M., Krönke, J., Bullinger, L., Späth, D., Kayser, S., Zucknick, M., Götze, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3762 · Cited by 801
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation
Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., Gross, S., et al. (2012) · Nature · doi:10.1038/nature10898 · Cited by 727 · cited 1×
“To further complicate the matter, D2HG has been reported to specifically increase the activity of the HIF1a hydroxylase EGLN in human astrocytes and colorectal cancer cells, leading to decreased levels of HIF1a protein.(60) Further work is required to elucidate the relationship between elevated D2HG levels in glioma a…”
BackgroundSelf-citationIDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas
Nobusawa, S., Watanabe, T., Kleihues, P., & Ohgaki, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0715 · Cited by 711
A vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 706
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
Losman, J.-A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C., Cowley, G. S., Root, D. E., Ebert, B. L., & Kaelin, W. G. (2013) · Science · doi:10.1126/science.1231677 · Cited by 703
IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas
Ichimura, K., Pearson, D. M., Kocialkowski, S., Bäcklund, L. M., Chan, R., Jones, D. T. W., & Collins, V. P. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-025 · Cited by 595
Frequent ATRX , CIC , FUBP1 and IDH1 mutations refine the classification of malignant gliomas
Jiao, Y., Killela, P. J., Reitman, Z. J., Rasheed, B. A., Heaphy, C. M., de Wilde, R. F., Rodriguez, F. J., Rosemberg, S., Oba-Shinjo, S. M., Nagahashi Marie, S. K., et al. (2012) · Oncotarget · doi:10.18632/oncotarget.588 · Cited by 584
Self-citationvan den Bent, M. J. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0725-7 · Cited by 577
Reitman, Z. J., & Yan, H. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq187 · Cited by 562 · cited 1×
“IDH mutations are universally missense substitutions and are almost invariably heterozygous.(39) – 41 Remarkably, mutations in IDH1 and IDH2 occur only at specific arginine residues in the active sites of these enzymes (Table 1).”
BackgroundSelf-citationKhanna, C., Anderson, P. M., Hasz, D. E., Katsanis, E., Neville, M., & Klausner, J. S. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970401)79:7 · Cited by 561
Pansuriya, T. C., van Eijk, R., d'Adamo, P., van Ruler, M. A. J. H., Kuijjer, M. L., Oosting, J., Cleton-Jansen, A.-M., van Oosterwijk, J. G., Verbeke, S. L. J., Meijer, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.1004 · Cited by 559
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Bettegowda, C., Agrawal, N., Jiao, Y., Sausen, M., Wood, L. D., Hruban, R. H., Rodriguez, F. J., Cahill, D. P., McLendon, R., Riggins, G., et al. (2011) · Science · doi:10.1126/science.1210557 · Cited by 553
Self-citationIDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
Houillier, C., Wang, X., Kaloshi, G., Mokhtari, K., Guillevin, R., Laffaire, J., Paris, S., Boisselier, B., Idbaih, A., Laigle-Donadey, F., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f96282 · Cited by 535
Yan, H., Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.18 · Cited by 529
Self-citationInhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1666 · Cited by 513
Oncogenic Isocitrate Dehydrogenase Mutations: Mechanisms, Models, and Clinical Opportunities
Cairns, R. A., & Mak, T. W. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0083 · Cited by 452
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome
Reitman, Z. J., Jin, G., Karoly, E. D., Spasojevic, I., Yang, J., Kinzler, K. W., He, Y., Bigner, D. D., Vogelstein, B., & Yan, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019393108 · Cited by 449
Self-citationLai, A., Kharbanda, S., Pope, W. B., Tran, A., Solis, O. E., Peale, F., Forrest, W. F., Pujara, K., Carrillo, J. A., Pandita, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.8715 · Cited by 433
Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2
Amary, M. F., Damato, S., Halai, D., Eskandarpour, M., Berisha, F., Bonar, F., McCarthy, S., Fantin, V. R., Straley, K. S., Lobo, S., et al. (2011) · Nature Genetics · doi:10.1038/ng.994 · Cited by 428
Cytosolic NADP+-dependent isocitrate dehydrogenase status modulates oxidative damage to cells
Lee, S. M., Koh, H.-J., Park, D.-C., Song, B. J., Huh, T.-L., & Park, J.-W. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00815-8 · Cited by 422
Xu, X., Zhao, J., Xu, Z., Peng, B., Huang, Q., Arnold, E., & Ding, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404298200 · Cited by 403
Bleeker, F. E., Lamba, S., Leenstra, S., Troost, D., Hulsebos, T., Vandertop, W. P., Frattini, M., Molinari, F., Knowles, M., Cerrato, A., et al. (2009) · Human Mutation · doi:10.1002/humu.20937 · Cited by 363
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers
Kang, M. R., Kim, M. S., Oh, J. E., Kim, Y. R., Song, S. Y., Seo, S. I., Lee, J. Y., Yoo, N. J., & Lee, S. H. (2009) · International Journal of Cancer · doi:10.1002/ijc.24379 · Cited by 313
Weller, M., Weber, R. G., Willscher, E., Riehmer, V., Hentschel, B., Kreuz, M., Felsberg, J., Beyer, U., Löffler-Wirth, H., Kaulich, K., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1409-0 · Cited by 312
Bleeker, F. E., Atai, N. A., Lamba, S., Jonker, A., Rijkeboer, D., Bosch, K. S., Tigchelaar, W., Troost, D., Vandertop, W. P., Bardelli, A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0645-6 · Cited by 302
Sasaki, M., Knobbe, C. B., Itsumi, M., Elia, A. J., Harris, I. S., Chio, I. I. C., Cairns, R. A., McCracken, S., Wakeham, A., Haight, J., et al. (2012) · Genes & Development · doi:10.1101/gad.198200.112 · Cited by 296 · cited 3×
“Similarly, Sasaki et al generated a heterozygous IDH1 knock-in mouse model and found that IDH1 expression in mouse neural stem cells is sufficient to inhibit global 5-hmC levels.(53) This finding is consistent with observations in glioma tissue, in which 5-hmC levels are lower in IDH-mutant gliomas relative to IDH gli…”
BackgroundResultInfluentialWhole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kannan, K., Inagaki, A., Silber, J., Gorovets, D., Zhang, J., Kastenhuber, E. R., Heguy, A., Petrini, J. H., Chan, T. A., & Huse, J. T. (2012) · Oncotarget · doi:10.18632/oncotarget.689 · Cited by 278
Killela, P. J., Pirozzi, C. J., Healy, P., Reitman, Z. J., Lipp, E., Rasheed, B. A., Yang, R., Diplas, B. H., Wang, Z., Greer, P. K., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1765 · Cited by 263
Self-citationAll the 1p19q codeleted gliomas are mutated on IDH1 or IDH2
Labussière, M., Idbaih, A., Wang, X.-W., Marie, Y., Boisselier, B., Falet, C., Paris, S., Laffaire, J., Carpentier, C., Crinière, E., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e1cf3a · Cited by 260
Cytosolic NADP+-dependent Isocitrate Dehydrogenase Plays a Key Role in Lipid Metabolism
Koh, H.-J., Lee, S.-M., Son, B.-G., Lee, S.-H., Ryoo, Z. Y., Chang, K.-T., Park, J.-W., Park, D.-C., Song, B. J., Veech, R. L., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402260200 · Cited by 251
(1994) · PubMed · Cited by 244
Turcan, S., Fabius, A. W. M., Borodovsky, A., Pedraza, A., Brennan, C., Huse, J., Viale, A., Riggins, G. J., & Chan, T. A. (2013) · Oncotarget · doi:10.18632/oncotarget.1412 · Cited by 240
Ronnebaum, S. M., Ilkayeva, O., Burgess, S. C., Joseph, J. W., Lu, D., Stevens, R. D., Becker, T. C., Sherry, A. D., Newgard, C. B., & Jensen, M. V. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511908200 · Cited by 230
Regulation of hypoxia-inducible factor 1 by prolyl and asparaginyl hydroxylases
Hirota, K., & Semenza, G. L. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.08.193 · Cited by 229
Structure of a bacterial enzyme regulated by phosphorylation, isocitrate dehydrogenase.
Hurley, J. H., Thorsness, P. E., Ramalingam, V, Helmers, N. H., Koshland, D. E., & Stroud, R. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.22.8635 · Cited by 207
TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations
Labussière, M., Di Stefano, A. L., Gleize, V, Boisselier, B., Giry, M., Mangesius, S., Bruno, A., Paterra, R., Marie, Y., Rahimian, A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.538 · Cited by 202
Wiestler, B., Capper, D., Sill, M., Jones, D. T. W., Hovestadt, V., Sturm, D., Koelsche, C., Bertoni, A., Schweizer, L., Korshunov, A., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1315-x · Cited by 194
Huang, D.-S., Wang, Z., He, X.-J., Diplas, B. H., Yang, R., Killela, P. J., Meng, Q., Ye, Z.-Y., Wang, W., Jiang, X.-T., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.010 · Cited by 193
Self-citationWakimoto, H., Tanaka, S., Curry, W. T., Loebel, F., Zhao, D., Tateishi, K., Chen, J., Klofas, L. K., Lelic, N., Kim, J. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3052 · Cited by 190 · cited 1×
“In malignant glioma, mutant IDH proteins are almost ubiquitously expressed in tumor cells, and IDH mutations precede secondary and tertiary genetic lesions, suggesting that IDH mutations are an early causative event in the genesis of this brain tumor subset.(23,29,38) IDH mutations are universally missense substitutio…”
BackgroundFilipp, F. V., Scott, D. A., Ronai, Z. A., Osterman, A. L., & Smith, J. W. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2012.00989.x · Cited by 185
Kernytsky, A., Wang, F., Hansen, E., Schalm, S., Straley, K., Gliser, C., Yang, H., Travins, J., Murray, S., Dorsch, M., et al. (2015) · Blood · doi:10.1182/blood-2013-10-533604 · Cited by 172
Insights from retinitis pigmentosa into the roles of isocitrate dehydrogenases in the Krebs cycle
Hartong, D. T., Dange, M., McGee, T. L., Berson, E. L., Dryja, T. P., & Colman, R. F. (2008) · Nature Genetics · doi:10.1038/ng.223 · Cited by 171
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate
Andronesi, O. C., Rapalino, O., Gerstner, E., Chi, A., Batchelor, T. T., Cahill, D. P., Sorensen, A. G., & Rosen, B. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67229 · Cited by 171
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas
Sahm, F., Koelsche, C., Meyer, J., Pusch, S., Lindenberg, K., Mueller, W. C., Herold‐Mende, C. C., von Deimling, A., & Hartmann, C. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0993-5 · Cited by 168
What do we know about IDH1/2 mutations so far, and how do we use it?
Horbinski, C. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1106-9 · Cited by 166
Leonardi, R., Subramanian, C., Jackowski, S., & Rock, C. O. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.c112.353946 · Cited by 163
Mutant IDH1 Confers an in Vivo Growth in a Melanoma Cell Line with BRAF Mutation
Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y., & Yamazaki, N. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.011 · Cited by 140
TP53 Gene Mutations and 17p Deletions in Human Astrocytomas
Chung, R. Y., Whaley, J. M., Kley, N., Anderson, K., Louis, D. N., Menon, A. G., Hettlich, C., Freiman, R. N., Hedley‐Whyte, E. T., Martuza, R. L., et al. (1991) · Genes Chromosomes and Cancer · doi:10.1002/gcc.2870030502 · Cited by 132
Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation
Ohka, F., Ito, M., Ranjit, M., Senga, T., Motomura, A., Motomura, K., Saito, K., Kato, K., Kato, Y., Wakabayashi, T., et al. (2014) · Tumor Biology · doi:10.1007/s13277-014-1784-5 · Cited by 128
van den Bent, M. J., Erdem‐Eraslan, L., Idbaïh, A., de Rooi, J., Eilers, P. H. C., Spliet, W. G. M., den Dunnen, W. F. A., Tijssen, C. C., Wesseling, P., Smitt, P. A. E. S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1157 · Cited by 127
Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
Pellegatta, S., Valletta, L., Corbetta, C., Patanè, M., Zucca, I., Sirtori, F. R., Bruzzone, M. G., Fogliatto, G., Isacchi, A., Pollo, B., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0180-0 · Cited by 127
TERT promoter mutations contribute to subset prognostication of lower-grade gliomas
Chan, A. K., Yao, Y., Zhang, Z., Chung, N. Y., Liu, J. S.-M., Li, K. K., Shi, Z., Chan, D. T. M., Poon, W. S., Zhou, L., et al. (2014) · Modern Pathology · doi:10.1038/modpathol.2014.94 · Cited by 118
Hominoid-specific enzyme GLUD2 promotes growth of IDH1 R132H glioma
Chen, R., Nishimura, M. C., Kharbanda, S., Peale, F., Deng, Y., Daemen, A., Forrest, W. F., Kwong, M., Hedehus, M., Hatzivassiliou, G., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1409653111 · Cited by 117
Jin, G., Reitman, Z. J., Spasojevic, I., Batinic-Haberle, I., Yang, J., Schmidt-Kittler, O., Bigner, D. D., & Yan, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016812 · Cited by 112 · cited 1×
“Subsequent studies confirmed this result and further demonstrated that leukemia-associated IDH2 mutations at Arg(140), which is adjacent to IDH2 Arg(172) in the active site, conferred an identical neomorphic function to produce D2HG from aKG.(9,46) The identification of recurrent IDH mutations in glioma and leukemia u…”
BackgroundSelf-citationMultiple NADPH-producing pathways control glutathione (GSH) content in retina
Winkler, B. S., Desantis, N. M., & Solomon, F. (1986) · Experimental Eye Research · doi:10.1016/s0014-4835(86)80013-6 · Cited by 107
IL-6 and Akt are involved in muscular pathogenesis in myasthenia gravis
Maurer, M., Bougoin, S. V., Feferman, T., Frenkian, M., Bismuth, J., Mouly, V., Cizeron-Clairac, G., Tzartos, S. J., Fadel, É., Eymard, B., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0179-6 · Cited by 107
Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma
Guan, X., Vengoechea, J. E., Zheng, S., Sloan, A. E., Chen, Y., Brat, D. J., O’Neill, B. P., de Groot, J., Yust‐Katz, S., Yung, W.-K. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091216 · Cited by 106
Reitman, Z. J., Duncan, C. G., Poteet, E. C., Winters, A., Yan, L., Gooden, D. M., Spasojević, I., Boros, L. G., Yang, S.-H., & Yan, H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.575183 · Cited by 97
Self-citationMetabolic Reprogramming in Mutant IDH1 Glioma Cells
Izquierdo-García, J. L., Viswanath, P., Eriksson, P., Chaumeil, M. M., Pieper, R. O., Phillips, J. J., & Ronen, S. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118781 · Cited by 90
The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas
Juratli, T. A., Kirsch, M., Geiger, K. D., Klink, B., Leipnitz, E., Pinzer, T., Soucek, S., Schrok, E., Schackert, G., & Krex, D. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-012-0977-2 · Cited by 86
The genetic landscape of anaplastic astrocytoma
Killela, P. J., Pirozzi, C. J., Reitman, Z. J., Jones, S., Rasheed, B. A., Lipp, E., Friedman, H. S., Friedman, A. H., He, Y., McLendon, R. E., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1505 · Cited by 80
Self-citationReverse flux through cardiac NADP+-isocitrate dehydrogenase under normoxia and ischemia
Comte, B., Vincent, G., Bouchard, B., Benderdour, M., & Rosiers, C. D. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00287.2002 · Cited by 69
Kim, S.-Y., & Park, J. (2003) · Free Radical Research · doi:10.1080/1071576021000050429 · Cited by 62
Lopez, G. Y., Reitman, Z. J., Solomon, D. A., Waldman, T. A., Bigner, D. D., McLendon, R. E., Rosenberg, S. A., Samuels, Y., & Yan, H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.06.125 · Cited by 59
Self-citationJo, S., Lee, S.-H., Chun, H., Lee, S. M., Koh, H., Lee, S., Chun, J., Park, J., & Huh, T. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6667 · Cited by 58
Kim, J., Kim, K. Y., Jang, H., Yoshida, T., Tsuchiya, K., Nitta, K., Park, J., Bonventre, J. V., & Park, K. M. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90566.2008 · Cited by 51
Regulation of replicative senescence by NADP+-dependent isocitrate dehydrogenase
Kil, I. S., Huh, T. L., Lee, Y. S., Lee, Y. M., & Park, J. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.08.021 · Cited by 44
MacDonald, M. J., Brown, L. J., Longacre, M. J., Stoker, S. W., Kendrick, M. A., & Hasan, N. M. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.07.013 · Cited by 41
Qi, S.-Τ. (2011) · Oncology Reports · doi:10.3892/or.2011.1428 · Cited by 33
Enzyme redesign guided by cancer-derived IDH1 mutations
Reitman, Z. J., Choi, B. D., Spasojević, I., Bigner, D. D., Sampson, J. H., & Yan, H. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1065 · Cited by 25
Self-citationKim, J., Kim, J. I., Jang, H., Park, J., & Park, K. M. (2011) · Free Radical Research · doi:10.3109/10715762.2011.577426 · Cited by 20
IDH1 regulates phospholipid metabolism in developing astrocytes
Bogdanovic, E., Sadri, A.-R., Catapano, M. S., Vance, J. E., & Jeschke, M. G. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.09.015 · Cited by 14
Cited by
Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Bunse, L., Pusch, S., Bunse, T., Sahm, F., Sanghvi, K., Friedrich, M., Alansary, D., Sonner, J. K., Green, E., Deumelandt, K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0095-6 · Cited by 539
Altered cellular metabolism in gliomas — an emerging landscape of actionable co-dependency targets
Bi, J., Chowdhry, S., Wu, S., Zhang, W., Masui, K., & Mischel, P. S. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0226-5 · Cited by 353
Metabolic Reprogramming in Glioma
Strickland, M., & Stoll, E. A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00043 · Cited by 345
Biological Role and Therapeutic Potential of IDH Mutations in Cancer
Waitkus, M. S., Diplas, B. H., & Yan, H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.011 · Cited by 335
Self-citationThe 2016 World Health Organization classification of tumours of the central nervous system
Villa, C., Miquel, C., Mosses, D., Bernier, M., & Di Stefano, A. L. (2018) · La Presse Médicale · doi:10.1016/j.lpm.2018.04.015 · Cited by 319
Metadata
- Authors
- Waitkus, M. S., Diplas, B. H., & Yan, H.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-07-16
- Volume
- 18
- Issue
- 1
- Pages
- 16-26
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W1824539338
- Cited by
- 282
- References
- 104
- FWCI
- 12.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.